4月27日 - ** 生物科技公司Mirum Pharmaceuticals MIRM.O的股价在盘前交易中上涨2%，报92.99美元
** 该公司表示，其实验性药物brelovitug在一项针对慢性丁型肝炎的中期研究中达到了主要目标。丁型肝炎是一种严重的肝脏感染，可能迅速导致肝衰竭
** 数据显示，低剂量组100%的患者和高剂量组75%的患者在24周后病毒载量显著下降，而对照组无一例出现此情况
** 称多达45%的受试患者肝酶水平恢复正常，这表明肝脏健康状况有所改善
** 补充称该药物耐受性良好，严重副作用极少
** 预计2026年下半年将公布晚期临床试验数据，并可能于2027年在美国上市
** 截至上一交易日收盘，该股年内累计涨幅约16%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.